Skip to content
Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

BridgeBio Oncology Therapeutics, Inc. (BBOT)

A forensic read on BridgeBio Oncology Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective
Forensic grade
Grey Zone
Financial health
12.6
Distress distance
1
Forensic signals
-115.3%
ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

BridgeBio Oncology Therapeutics, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 12.6, placing it in the Grey zone. 1 forensic signal was flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+241276.2%/yr
FY2024–FY2025
Share-count dilution. Diluted share count changed +241276% over the last 1 year to FY2025 (+241276.2%/yr). The count is growing — 0.0M shares in FY2024, 31.1M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~241276.2% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2024 has been diluted ~100%.

Key fundamentals

Free Cash Flow-$114.5M
Return on Equity-115.3%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from BridgeBio Oncology Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.